MedinCell

Company Description

Medincell SA is a France-based manufacturer of biological products and pharmaceutical preparations. The company develops therapeutic solutions with worldwide access, collaborating with pharmaceutical corporations, physicians, biotechnology firms, academics, and foundations. Their main businesses include developing long-acting injectable medicines for various therapeutic areas such as schizophrenia, post-surgical pain and inflammation, contraception, and depression. In the last fiscal year, the company had a market cap of $622 million and revenue of $27 million.

Analysis

ANALYSIS: With an Obermatt 360° View of 14 (better than 14% compared with alternatives), overall professional sentiment and financial characteristics for the stock MedinCell are critical, mostly below average. The 360° View is based on consolidating four consolidated indicators, with half of the metrics below and half above average for MedinCell. The consolidated Growth Rank has a good rank of 67, which means that the company experiences above-average growth momentum when looking at financial metrics such as revenue, profit, and invested capital growth as well as stock returns. This means that growth is higher than for 67% of competitors in the same industry. The consolidated Sentiment Rank also has a good rank of 53, which means that professional investors are more optimistic about the stock than for 53% of alternative investment opportunities. But the consolidated Value Rank has a less desirable rank of 15, which means that the share price of MedinCell is on the higher side compared with typical size in indicators such as revenues, profits, and invested capital. This means the stock price is higher than for 85% of alternative stocks in the same industry. Finally, the consolidated Safety Rank has a riskier rank of 6, which means that the company has a financing structure that is riskier than those of 94% comparable companies when looking at the amount of its debt, its refinancing requirements, and its ability to service debt. ...read more

Country

France

Industry Pharmaceuticals

Size X-Small

Website medincell.com

Index

CAC All

Add to Watchlist

See Similar Stocks

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.